We give you a written timeline estimate for your case before you commit.Ask about treatment
Chronic rhinosinusitis (CRS) with nasal polyps: US-approved treatments and how families in the Gulf can access them
A plain guide for families in the Gulf, checked against US FDA labels, US National Institutes of Health information, Gulf drug registers and published research on 17 October 2026.
Reviewed by the Reserve Meds clinical operations team on 17 October 2026.
Chronic rhinosinusitis with nasal polyps: the short answer
The US FDA has approved four medicines covered on this page for chronic rhinosinusitis with nasal polyps, each for a specific group of patients: Dupixent, Nucala, Xolair and Tezspire. On 17 October 2026, four of them were on the Saudi or Abu Dhabi register, so ask your hospital about local supply first. Where a medicine is not registered, the treating hospital can ask the national regulator to import it for one named patient. Reserve Meds is a digital health company that helps with that process. We do not diagnose or prescribe.
- US FDA-approved medicines on this page: Dupixent, Nucala, Xolair and Tezspire.
- Gulf registers (checked 17 October 2026): see each medicine below.
- Legal route: local supply where listed; otherwise a named-patient import request filed by the treating hospital.
- Price: Quote on request.
What is chronic rhinosinusitis with nasal polyps?
Sinusitis means the sinuses, the hollow air spaces in the bones around the nose, are inflamed. Chronic sinusitis lasts more than 12 weeks and can continue for months or even years. Allergies, nasal problems and certain diseases can cause it.[1]
Symptoms can include congestion, mucus draining down the back of the throat, cough and fatigue. Some people with chronic rhinosinusitis also have nasal polyps, a form the US labels call chronic rhinosinusitis with nasal polyps (CRSwNP).[1, 2]
For adults whose disease stays inadequately controlled, several biologic medicines are approved in the US as add-on maintenance treatment for chronic rhinosinusitis with nasal polyps (CRSwNP).[2, 3, 4, 5]
Chronic rhinosinusitis with nasal polyps in the Gulf
Gulf ear, nose and throat specialists have published on chronic rhinosinusitis, including a phenotype-based study of severe asthma in Kuwait and a retrospective analysis of chronic rhinosinusitis symptoms after COVID-19.[6, 7]
We checked every medicine on this page against the full SFDA drugs list and the Abu Dhabi Department of Health drug code list on 17 October 2026. 4 of 4 were listed in Saudi Arabia and 4 of 4 in Abu Dhabi. The result for each medicine is shown below. A listing does not mean every hospital stocks the medicine, and federal UAE, Kuwait, Qatar, Bahrain and Oman registers were not checked.[8, 9]
US FDA-approved medicines for chronic rhinosinusitis with nasal polyps
Each medicine below is approved in the US for a specific group of patients. The wording summarizes the current US label. Your specialist decides whether any of them is right for the patient.
- Dupixent (dupilumab)
US FDA-approved for add-on maintenance treatment of inadequately controlled CRSwNP in adults and children 12 and older, and allergic fungal rhinosinusitis in patients 6 and older. It is an injection under the skin.[2]
Current US label version: 22 April 2026. Gulf registers: Saudi Arabia (SFDA drugs list): listed. Abu Dhabi (DoH drug code list): listed. Checked 17 October 2026. Federal UAE, Kuwait, Qatar, Bahrain and Oman: not checked; we confirm for your country when you ask.[8, 9]
Country access guides: Saudi Arabia, UAE, Kuwait, Qatar - Nucala (mepolizumab)
US FDA-approved for add-on maintenance treatment of CRSwNP in adults 18 and older. It is an injection under the skin.[3]
Current US label version: 6 August 2025. Gulf registers: Saudi Arabia (SFDA drugs list): listed. Abu Dhabi (DoH drug code list): listed. Checked 17 October 2026. Federal UAE, Kuwait, Qatar, Bahrain and Oman: not checked; we confirm for your country when you ask.[8, 9]
Country access guides: Saudi Arabia, UAE, Kuwait, Qatar - Xolair (omalizumab)
US FDA-approved for add-on maintenance treatment of CRSwNP in adults with an inadequate response to nasal steroids. It is an injection under the skin.[4]
Current US label version: 13 August 2026. Gulf registers: Saudi Arabia (SFDA drugs list): listed. Abu Dhabi (DoH drug code list): listed. Checked 17 October 2026. Federal UAE, Kuwait, Qatar, Bahrain and Oman: not checked; we confirm for your country when you ask.[8, 9]
Country access guides: Saudi Arabia, UAE, Kuwait, Qatar - Tezspire (tezepelumab-ekko)
US FDA-approved for add-on maintenance treatment of inadequately controlled CRSwNP in adults and children 12 and older. It is an injection under the skin.[5]
Current US label version: 17 October 2025. Gulf registers: Saudi Arabia (SFDA drugs list): listed. Abu Dhabi (DoH drug code list): listed. Checked 17 October 2026. Federal UAE, Kuwait, Qatar, Bahrain and Oman: not checked; we confirm for your country when you ask.[8, 9]
Country access guides: Saudi Arabia, UAE, Kuwait, Qatar
How families in the Gulf can access treatment
If the medicine is listed in your country. Ask your specialist and the hospital about local supply first. A listing does not mean every hospital stocks the medicine, but it is usually the fastest route, and you may not need us.
If it is not registered. The usual legal route is a named-patient request: the treating hospital, on your specialist's written request, asks the national regulator for permission to import the medicine for one patient, using the US FDA approval as the reference. In Saudi Arabia the SFDA Special Access Program guidance covers these requests; in Bahrain, NHRA Circular 41 of 2020 sets the procedure. Other Gulf countries have their own procedures, which the hospital confirms.[10, 11] Once approval is in place, Reserve Meds arranges supply through a US-licensed pharmaceutical wholesale partner to the hospital.
Who does what
- Your treating specialist decides whether a medicine is right for the patient and writes the medical letter.
- The hospital checks local supply, files any import request, and gives the treatment safely.
- The national regulator decides whether to approve the import of a medicine that is not registered.
- The manufacturer decides where its medicine can be supplied, especially for cell and gene therapies.
- Reserve Meds helps organize records, coordinates US supply through our wholesale partner, shipping and updates to your family. We do not give medical advice.
Documents you will usually need
- A letter from the treating specialist with the diagnosis, past treatments and why this medicine is being considered
- Reports that confirm the diagnosis, such as genetic, pathology, imaging or laboratory results, translated into English where needed
- Recent clinic notes and a list of current medicines
- For a hospital import request: the prescription, the hospital's request form and the written consent of the patient or guardian
- Proof of the US FDA approval and the US prescribing information (we can supply these)
We give you a written timeline estimate for your case before you commit. The regulator, the hospital or treatment center and the manufacturer set their own timelines.
What treatment costs
Quote on request. Your total cost depends on the medicine, the dose, shipping, import steps and coordination. Your coordination fee is quoted in writing for your case before you commit. No hidden charges.
How Reserve Meds helps
Reserve Meds is a digital health company. Medicines are supplied through a US-licensed pharmaceutical wholesale partner. We help your doctor and hospital prepare the file, arrange US supply and temperature-controlled shipping once approval is in place, and keep your family updated. We coordinate access to FDA-approved medicines only. Investigational medicines are only available through a manufacturer's expanded-access program requested by the treating physician; we can explain that route, but we do not supply them.
Ask us about treatment for chronic rhinosinusitis with nasal polyps
Tell us the medicine, your country and a WhatsApp or phone number. We reply within one business day. On WhatsApp we usually reply the same day.
Frequently asked questions
Is there an FDA-approved treatment for chronic rhinosinusitis with nasal polyps?
Yes. The medicines on this page have US FDA approval for specific groups of patients: Dupixent, Nucala, Xolair and Tezspire. The exact conditions are in each US label and are summarized above. Your specialist decides whether any of them fits.
Is Dupixent available in Saudi Arabia or the UAE?
We checked on 17 October 2026. Saudi Arabia (SFDA drugs list): listed. Abu Dhabi (Department of Health drug code list): listed. A listing in Abu Dhabi does not show federal UAE status, which we could not verify. Your hospital confirms current supply.
How can a family in the Gulf get Dupixent?
Ask the treating hospital about local supply first. If it is not available, the hospital can file a named-patient import request with the national regulator on your specialist's written request. Once approved, we arrange US supply to the hospital.
How much does treatment cost?
Quote on request. Your total cost, including the medicine, shipping, import steps and coordination, is quoted in writing for your case before you commit. No hidden charges.
Does Reserve Meds diagnose or prescribe?
No. Reserve Meds is a digital health company. Medicines are supplied through a US-licensed pharmaceutical wholesale partner. We do not diagnose, prescribe or decide what a regulator approves. Your specialist and hospital make the medical decisions.
Do these medicines replace sinus surgery?
They are add-on maintenance treatments for nasal polyps that remain inadequately controlled. Your ear, nose and throat specialist decides how they fit with nasal sprays and surgery.
Sources for the condition-specific answers: [2, 5]
Sources
Accessed and checked on 17 October 2026. Labels, registers and regulator rules change. Your hospital confirms the current position before anything is filed.
- MedlinePlus (US National Library of Medicine): Sinus Infection
- DailyMed: DUPIXENT (dupilumab) US prescribing information, label version 22 April 2026
- DailyMed: NUCALA (mepolizumab) US prescribing information, label version 6 August 2025
- DailyMed: XOLAIR (omalizumab) US prescribing information, label version 13 August 2026
- DailyMed: TEZSPIRE (tezepelumab-ekko) US prescribing information, label version 17 October 2025
- Al-Ahmad M, et al. Severe asthma in Kuwait population: Phenotype-based approach. Respir Med. 2021 (PubMed 34474336)
- Alroqi A, et al. Evaluation of Chronic Rhinosinusitis Symptoms' Severity Following COVID-19 Infection: A Retrospective Analysis. Cureus. 2023 (PubMed 37288207)
- SFDA: Drugs List, public register (all 9,173 entries checked by brand name on 17 October 2026)
- Department of Health Abu Dhabi: drug code list Drugs.xlsx (release 26 September 2026, effective 2 October 2026)
- SFDA: Special Access Program (SAP) guidance, version 1.0
- NHRA Bahrain: Circular No. (41) of 2020, procedures for importing non-registered medicines and pharmaceutical products
Related
- COPD
- Chronic spontaneous urticaria
- Eosinophilic esophagitis (EoE)
- Dupixent: drug overview
- Nucala: drug overview
- Xolair: drug overview
- Named-patient access in the Gulf, explained
- US-approved medicines not yet registered in the Gulf
- Answers to common access questions
- Cross-border disclosures
- اقرأ هذه الصفحة بالعربية
This page is general health information, not medical advice. It does not replace a consultation with your doctor.